Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

The study included 7881 patients: 6109 and 1772 received semaglutide and tirzepatide, respectively; 80.8% had low maintenance dosages.

Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. ・Tumor size closely matched body weight and fat levels, suggesting fat ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer and weight-loss therapy.

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the changes were more pronounced in women, researchers reported at ENDO 2025.

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, Chinese obese individuals can maintain significant ...

Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and ...

HealthDay News — For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction, according to a study ...

The study included 7,881 patients: 6,109 and 1,772 received semaglutide and tirzepatide, respectively; 80.8 percent had low maintenance dosages.